Clinical trials: Hormone Disturbance
Type 2 Diabetes Mellitus
Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to examine the participant's preference for treatment with once-weekly dosing of DPP-4 inhibitor trelagliptin versus once-daily dosing of DPP-4 inhibitor alogliptin among the participants with type 2…
- Trial name
- TRINITY (NCT03231709)
- Testing
- Trelagliptin, Alogliptin
- Where
- 2 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Takeda
Ovarian Neoplasms
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
The purpose of the study is to compare the efficacy and safety of 2 doses of drug AZD2281 against liposomal doxorubicin to see which is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive…
- Trial name
- ICEBERG 3 (NCT00628251)
- Testing
- AZD2281, Liposomal Doxorubicin
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 97 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control…
- Trial name
- NCT01106651
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s)
- Where
- 86 sites in United States, Australia and 15 more
- Volunteers
- 716 people
- Sponsor
- Janssen Research & Development, LLC
Hypogonadism
Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™
Multicenter study consisting of two study periods as follows: a 90-day Treatment Period, with potential extension by 30 days for those patients requiring a dose increase, as determined by the treating physician.
- Trial name
- MyT (NCT02937740)
- Testing
- NATESTO Testosterone Nasal Gel
- Where
- 11 sites in Canada
- Volunteers
- 117 people
- Sponsor
- Acerus Pharmaceuticals Corporation
Type 2 Diabetes Mellitus
A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)
This study will evaluate the efficacy and safety of ertugliflozin (MK-8835/PF-04971729) in participants with Type 2 diabetes mellitus with Stage 3 Chronic Kidney Disease (CKD) who have inadequate glycemic control on background…
- Trial name
- NCT01986855
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 10 mg
- Volunteers
- 468 people
- Sponsor
- Merck Sharp & Dohme LLC
Ovarian Carcinoma, Soft Tissue Sarcoma
Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
A phase Ib trial study of trabectedin when prescribed in combination with durvalumab in locally advanced/unresectable soft-tissue sarcoma and ovarian carcinomas.
- Trial name
- TRAMUNE (NCT03085225)
- Testing
- Combination of trabectedin with durvalumab
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Institut Bergonié
Type 2 Diabetes
Liraglutide Hospital Discharge Trial
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- NCT01919489
- Testing
- Liraglutide + OADs, Glargine + OADs
- Where
- 5 sites in United States
- Volunteers
- 273 people
- Sponsor
- Emory University
Diabetes Mellitus, Type 2
A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02390050
- Testing
- Bexagliflozin tablets
- Where
- 50 sites in United States, Japan
- Volunteers
- 292 people
- Sponsor
- Theracos
Schizophrenia, Schizoaffective Disorder
Ramelteon as an Adjunct Therapy in Non-Diabetic Patients With Schizophrenia
This study involves people who have schizophrenia or schizoaffective disorder who are currently taking antipsychotic medications.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
- Trial name
- NCT00595504
- Testing
- Ramelteon
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Massachusetts General Hospital
Diabetes
Soccer-based Adaptation of the Diabetes Prevention Program
This is a longitudinal pre-post pilot intervention study evaluating feasibility of implementation of a soccer-based Diabetes Prevention Program (DPP) and preliminary changes in physical activity and diet-related measures.
- Trial name
- NCT03595384
- Testing
- Soccer-based adaptation to the DPP
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Emory University
Type 2 Diabetes Mellitus
Pharmacokinetics Study of Dipeptidyl Peptidase 4 Inhibitor to Control Type 2 Diabetes Mellitus
The purpose of this study is to confirm the mechanism of reduced response to DPP-4 inhibitor in some patients with type 2 diabetes and evaluate appropriate patients to treat with DPP-4 inhibitor
- Trial name
- NCT01449747
- Testing
- Sitagliptin
- Where
- 2 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- The Catholic University of Korea
Pancreatic Cancer
Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
There are limited treatment options available for patients with advanced pancreatic ductal adenocarcinoma (PDAC). The purpose of this study is to determine the effectiveness and safety of the drugs capecitabine and oxaliplatin in…
- Trial name
- NCT00585078
- Testing
- Capecitabine, Oxaliplatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Beth Israel Deaconess Medical Center
Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of ipilimumab when given together with gemcitabine hydrochloride in treating patients with stage III-IV or recurrent pancreatic cancer that cannot be removed by surgery.
- Conditions
- Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01473940
- Testing
- ipilimumab, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Northwestern University
Diabetes Mellitus, Type 2
A Study of LY2922470 in Healthy Participants and Participants With Diabetes
The aim of this trial is to evaluate the safety of the study drug in healthy participant and participant with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to…
- Trial name
- NCT01746017
- Testing
- LY2922470
- Where
- Singapore
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment.
- Trial name
- PIONEER 5 (NCT02827708)
- Testing
- semaglutide
- Where
- 117 sites in United States, Denmark and 6 more
- Volunteers
- 324 people
- Sponsor
- Novo Nordisk A/S
Eating Disorders, Type 1 Diabetes
Eating Disorder Prevention Program for Women With T1D
This study aims to test the effectiveness of an evidence-based eating- disorder prevention program specifically targeted for individuals with Type 1 Diabetes (T1D) compared to an educational control group.
- Trial name
- NCT05264376
- Testing
- Diabetes Body Project, Educational Control
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Stanford University
Diabetic Ketoacidosis, Type 1 Diabetes
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management
- Conditions
- Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
- Trial name
- NCT04567225
- Testing
- Early Glargine, Late Glargine, IV insulin infusion
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- The Cleveland Clinic
Diabetes Mellitus, Type 2
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT05465317
- Testing
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Where
- United States
- Volunteers
- 62,197 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes
Three-way, Cross-over Closed-loop Exercise Study
Blood glucose control systems that utilize both insulin and glucagon to manage blood sugar are paving the way to revolutionize the management of this disease.
- Trial name
- NCT02241889
- Testing
- Insulin pump therapy, Closed-loop Artificial Pancreas Controller
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to investigate the efficacy and safety of liraglutide in subjects with type 2 diabetes and moderate renal impairment.
- Trial name
- NCT01620489
- Testing
- liraglutide
- Where
- 97 sites in United States, France and 4 more
- Volunteers
- 279 people
- Sponsor
- Novo Nordisk A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.